STAT+: The Merck Covid-19 pill may be a game changer, but questions are already being raised about cost
Behind the unvarnished enthusiasm over an experimental Covid-19 pill, questions are emerging about the cost…
Category: drug pricing
STAT+: Three generic drug makers to pay $450 million to settle criminal price fixing charges
Three generic drug makers agreed to pay nearly $450 million to resolve civil allegations that…
STAT+: Key Senate committee considers a carveout for small biotech companies in drug pricing reforms
WASHINGTON — A key Senate panel is seriously considering a new policy that would soften…
Virtual Event: The evolving landscape for biosimilars
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
STAT+: Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited
Eli Lilly (LLY) announced plans to lower the wholesale price of certain insulin products by…
STAT+: Inflation and rebates caused wholesale prices on medicines to drop in second quarter
Amid continued political pressure on the pharmaceutical industry, a new analysis finds brand-name drug makers…
STAT+: In May, 10 moderate Democrats opposed major drug pricing reform. Ahead of a key vote, that list is shrinking
WASHINGTON — Ten House Democrats fired a warning shot in the spring that they could…
STAT+: WHO adds Regeneron drug to recommended Covid-19 treatments, but criticizes its pricing
The World Health Organization added a Regeneron Pharmaceuticals medication to its list of recommended treatments…
Opinion: Even me-too drugs matter when it comes to new medicines
As the government wrestles with lowering health care costs, one strategy gaining momentum is allowing…
STAT+: Federal officials move closer to penalizing drug makers for failing to offer discounts to safety-net hospitals
Following a year of controversy, the Health Resources and Services Administration is taking steps to…
Scott Gottlieb: Trump’s shadow FDA commissioner during Covid-19?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch
It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal…
Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch
It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal…
STAT+: U.S. lawmakers accuse patent office of weakening patent challenges and allowing drug prices to rise
A bipartisan group of lawmakers has accused the U.S. Patent & Trademark Office of “weakening”…
STAT+: Senate proposes expanding pharma penalties for hiking drug prices
WASHINGTON — A key Senate panel is expanding its plans to punish drug makers that…
STAT+: ‘A solid black eye’: Drug pricing reform advocates scramble to reset after setback in Congress
WASHINGTON — For the cadre of progressive groups fighting to bring down drug prices in…
Opinion: President Biden: Don’t misuse Bayh-Dole march-in rights
In a misguided attempt to control drug costs, some Congressional leaders are urging the Biden…
STAT+: A ‘wonky’ congressional report will be a pharma talking point in the drug pricing debate
As lawmakers in Washington grapple with legislation to alter the upward trajectory of prescription drug…
.jpg)
Moderate Democrats sink Pelosi’s aggressive drug pricing bill in key committee vote
WASHINGTON — House Speaker Nancy Pelosi’s aggressive drug pricing package failed a key committee vote…
STAT+: Safety-net hospitals take big markups on cancer drugs for commercially insured patients, study finds
Hospitals participating in a federal drug discount program marked up cancer medicines four times for…
Opinion: Congress is about to legislate a future without new medicines. We have a better plan
One of the fundamental principles on which the U.S. economy is based is that the…
Virtual Event: The 340B drug discount program is at a crossroads. What’s next?
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
STAT+: Key senator opposes Democrats’ target for drug-pricing savings
WASHINGTON — An influential Senate Democrat is pushing back against his party’s efforts to cut…
House moderates rebel against Pelosi drug pricing plan, leaving bill’s fate uncertain
WASHINGTON — Three moderate House Democrats are making good on their threat to oppose Speaker…
Opinion: Outdated rule increases Medicare’s costs for generic drugs by $26 billion a year
Public outcry about the shockingly high cost of brand-name drugs and a demand for new…
STAT+: Senate considers pegging Medicare drug prices to deeply discounted Veterans Affairs rates
WASHINGTON — Senate lawmakers are actively considering pegging the prices Medicare pays for drugs to…
New Biden plan to lower drug prices drawn from familiar Democratic playbook
WASHINGTON — The Biden administration on Thursday unveiled a long-awaited plan to lower prescription drug…
Congress is ready to dig into drug prices
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Opinion: To lower drug costs, define ‘cost’ to mean net cost after rebates
In what could be a turning point in the prescription drug debate, President Biden has…
STAT+: Democrats want to let Medicare negotiate drug prices. Has pharma found a way to lessen the blow, already?
WASHINGTON — As Democrats design a way to use the government’s leverage to lower drug…
STAT+: The 10 power players to watch on Democrats’ drug pricing push
WASHINGTON — In the coming weeks, Democrats will embark on an ambitious effort to change…
STAT+: WHO urges Roche to ensure equitable access of Covid-19 treatment amid global shortage
The World Health Organization and Unitaid called on Roche (RHHBY) to ensure that existing doses…
Listen: Biden’s drug pricing plan, Wall Street’s Alzheimer’s fixation, & daily 5 a.m. alarms
Can drug pricing help Democrats keep the Senate? Why is there still no nominee for…
STAT+: As Bluebird backpedals from Europe, small gene and cell therapy players face tough hurdles
After Bluebird Bio (BLUE) announced plans this week to end commercial operations in Europe, the…
In a new policy proposal, Biden presses Congress to let Medicare negotiate drug prices
President Biden on Thursday took his most concrete action to date on prescription drug prices,…
STAT+: Vulnerable Senate Democrats escalate a push for Medicare to negotiate drug prices
WASHINGTON — Five of the most vulnerable Democrats in the Senate on Tuesday publicly renewed…
STAT+: A federal appeals court throws into question the fate of ‘skinny labels’ — and access to generic drugs
In a decision with enormous implications for the U.S. health care system, a federal appeals…
STAT+: U.K. antitrust watchdog issues a provisional ruling that Pfizer engaged in price gouging
After being forced to reassess its original findings, a U.K. antitrust watchdog has issued a…
STAT+: Canadian agency loses a battle in effort to force a drug maker to lower ‘excessive’ pricing
In a withering ruling, a Canadian appeals court overturned a controversial decision issued four years…
STAT+: ‘Deeply disappointed’: FTC pulls pay-to-delay case after losing authority to force drug makers to relinquish profits
The Federal Trade Commission has reluctantly withdrawn a remaining claim in a lawsuit over a…
What happened to the FDA’s toughest regulator?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
Listen: Breakthrough infections, the power of lobbying, & pharma’s cinematic villainy
Did we take off our masks too soon? Can Democrats pass a drug pricing bill?…
STAT+: Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill
WASHINGTON — The very next day after Rep. Scott Peters attempted to torpedo House Speaker…
STAT+: Advocates urge Biden to name patent office director that could transform drug pricing
As the White House readies to name a new head of the U.S. Patent &…
STAT+: Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in the Netherlands have fined a drug maker $23 million for years of…
STAT+: U.K. issues record fine to drug makers for price gouging and collusion schemes
After a lengthy investigation, the U.K. antitrust regulator has fined several drug makers a record-setting…
STAT+: Senate Democrats eye drug pricing policies to fund $3.5 trillion budget deal
WASHINGTON — Senate Democrats intend to include several drug pricing policies in their $3.5 trillion…
STAT+: Biogen’s new Alzheimer’s drug could cost Medicaid up to $2.2 billion a year
A pricey new Alzheimer’s drug already mired in controversy could cost Medicaid anywhere from $720…
Biden wants a drug pricing plan in 45 days. Who’s going to write it?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: Biden’s executive order would pause a Trump rule forbidding march-in rights to lower drug costs
In a little-noticed move, the Biden administration has hit the pause button on a rule…